Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy
Fig 2
PLA2R1-ab levels, proteinuria, and serum creatinine in patients treated with immunosuppression, or supportive medication only.
PLA2R1-ab levels (A) and proteinuria (B) significantly decreased in patients treated with immunosuppression after three months (*) and between three and six months (ǁ). Serum creatinine increased in patients treated with immunosuppression after three months, but remained stable thereafter (C). At baseline patients treated with immunosuppressants had significantly higher PLA2R1-ab levels, proteinuria, and serum creatinine compared to patients who received no immunosuppression (§). The statistical significance was lost at six months for PLA2R1-ab, at nine months for proteinuria, but persisted for serum creatinine. In patients who received supportive treatment only the decrease of PLA2R1-ab levels and proteinuria reached statistical significance after nine months and six months, respectively. Time “0” shows data at the time of the first PLA2R1-ab measurement. ISupp.: Patients treated with immunosuppression. No ISupp.: patients treated with supportive medication only. “*” shows a statistically significant difference between the single time point and the start of the study (p<0.05). “ǁ” shows a statistically significant difference between the single time point and the time 3 months after study start (p<0.05). “§” shows a statistically significant difference between patients treated with immunosuppressive treatment and those who received supportive treatment only (p<0.05). PLA2R1-ab: PLA2R1 antibody.